Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech to Join the JETRO Healthcare Business Invitation Program in Japan
2025-09-30
Salipro Biotech is honored to be selected for the Chiba & Ibaraki Healthcare Business Invitation Program 2025, organized by JETRO.
From October 7–9, our BD Manager, Lorena, will be engaging with leading Japanese research institutions, innovation hubs, and companies in Ibaraki, Chiba, and Kanagawa, including participation in Bio Japan 2025.
With ongoing collaborations in Japan, we are excited to further strengthen our relations and explore new opportunities where the Salipro® platform can enable Japanese pharma and biotech companies in advancing their drug discovery programs towards challenging membrane proteins.
We look forward to this excellent opportunity to connect with potential local collaboration partners and gain insights into the Japanese life science innovation ecosystem!
Salipro Biotech to Bio Japan 2025
2025-09-22
We are participating in Bio Japan 2025, taking place in Yokohama from October 8-10!
Our Business Development team will be represented by:
Lorena Galán, attending in person on October 8 .
Peter Jahnmatz, available for virtual partnering meetings on October 9-10.
We look forward to connecting with pharma and biotech companies to discuss how the Salipro® platform can unlock drug discovery for complex membrane proteins, including GPCRs, ion channels, and SLC transporters.
Feel free to reach out via the partnering platform to schedule a meeting. We look forward to engaging with current and future partners in Japan and sharing how the Salipro® platform can drive the development of next-generation therapeutics!
New Study- Tackling Drug Resistance in Sleeping Sickness with Salipro®
2025-08-28
We are glad to highlight a recent publication in eLife, "Insights from aquaporin structures into drug-resistant sleeping sickness," which provides critical insights into the mechanisms of drug resistance in sleeping sickness.
The researchers solved the structure of the Trypanosoma brucei aquaporin TbAQP2. The findings reveal at a molecular level how essential drugs enter the parasite and, crucially, how mutations in this channel can lead to treatment failure.
Obtaining high-resolution structures of membrane proteins like TbAQP2 is often a significant technical challenge.
This work underscores the immense value of high-quality membrane protein structures in developing novel therapeutics against devastating diseases.
Congratulations to all the authors on this impactful publication!
Read the full paper here:
M. Matusevicius, R. A. Corey, M. Gragera, K. Yamashita, T. Sprenger, et al., Insights from aquaporin structures into drug-resistant sleeping sickness. eLife 14:RP107460 (2025).